Abstract:Objective: Chronic venous hypertension, triggered by venous reflux and/or obstruction, leads to skin changes and venous leg ulcers (VLUs). Compression therapy is the standard of care, but many wounds remain unhealed. The objectives of this study were to observe the effects of endovenous chemical ablation with commercially available 1% polidocanol injectable microfoam on VLU healing and recurrence rates. Methods: The VIEW VLU study was a multicenter, open-label, phase IV registry of patients with active VLUs resulting from venous insufficiency of the great saphenous vein and/or anterior accessory saphenous vein systems who underwent ablation with 1% polidocanol microfoam. Primary outcomes included wound healing rate (change in wound perimeter), wound closure at 12 weeks after treatment, and time to wound closure. Secondary outcomes included VLU recurrence, numeric pain score at the ulcer location, EuroQol five-dimension five-level questionnaire quality-of-life index, and the Venous Clinical Severity Score. Patients were followed for 12 months. Results: We enrolled 76 patients (80 ulcers) from 14 sites across the United States and Canada (mean age 63.6 ± 13.7 years, 39.5% female, mean body mass index 36.3). Of the enrollees, 96.3% presented with great saphenous vein incompetence. The mean baseline wound perimeter was 117.2 ± 107.4 mm and 26.3% of wounds (21/80) were circumferential. The mean ulcer age was 34.8 ± 51.8 weeks at first presentation and the mean compression therapy duration was 26.4 ± 35.9 weeks. The median wound perimeter decreased by 16.3% from baseline in the first 2 weeks after the procedure and by 27.0% at 12 weeks. By 12 weeks, 53.8% of wounds (43/80) were healed. The median time to ulcer closure by Kaplan-Meier analysis was 89 days (95% confidence interval, 62.0-117.0). In a Kaplan-Meier analysis of initially healed wounds, 88.9% (95% confidence interval, 76.9-94.8) remained closed at 12 weeks after closure. The mean numeric pain scores (ulcer site) improved by 41.0% and 64.1% at 12 weeks and 12 months after the procedure, respectively. The health-related quality-of-life index (scale of 0-1) improved from 0.65 ± 0.27 at baseline to 0.72 ± 0.28 at 12 weeks and 0.73 ± 0.30 at 12 months. By 12 weeks after treatment, the mean target leg Venous Clinical Severity Score had significantly decreased by 5.8 points, and by 12 months it had decreased by 10.0 points. Conclusions: Treatment with 1% polidocanol microfoam was associated with promising wound healing rates and low recurrence rates for VLUs, despite a challenging patient population with recalcitrant ulcers, a large percentage of which were circumferential, in patients with high body mass indexes.

Comparison of polidocanol foam versus bleomycin polidocanol foam for treatment of venous malformations

Comparison of bleomycin polidocanol foam versus electrochemotherapy combined with polidocanol foam for treatment of venous malformations

Clinical outcomes and predictors of bleomycin polidocanol foam sclerotherapy treatment response in venous malformations

Proven Protocol of Embolization and Sclerotherapy for Venous Malformation of Perineum

Percutaneous Sclerotherapy of Large Venous Malformations Using Consecutive Polidocanol and Bleomycin Foam: MR Imaging Volumetric and Quality-of-Life Assessment

Comparison Between Absolute Ethanol and Bleomycin for the Treatment of Venous Malformation in Children.

Foam Sclerotherapy in the Treatment of Hemangiomas and Venous Malformations.

Efficacy and safety of hyaluronic-polidocanol foam in sclerotherapy for head and neck venous malformations

A comparative study on radiofrequency endovenous obliteration (RFO) and saphenous veins stripping for the treatment of varicose veins

Impact of treatment of varicose veins with polidocanol foam compared to conventional surgery on quality of life

Polidocanol-foam treatment of varicose veins: Quality-of-life impact compared to conventional surgery

Sclerothrapy of giant lymphatic malformation in neonates

A clinical study of ultrasound-guided intralesional injection of bleomycin A5 on venous malformation in cervical-facial region in China.

First registry of patients treated with foam sclerotherapy using a new automated microfoam preparation device (2021-2022)

Bleomycin induces endothelial cell pyroptosis and regulates fibrosis by activating the NLRP3/caspase-1/GSDMD pathway: a possible mechanism contributing to the sclerotherapy of venous malformations

Effect of catheter needle caliber on polidocanol foam stability in foam sclerotherapy

Efficacy of Bleomycin-Lauromacrogol Foam in Pediatric Macrocystic Lymphatic Malformations With and Without Intracapsular Hemorrhage

Comparison of Foam Sclerotherapy Alone or Combined With Stripping of the Great Saphenous Vein for Treating Varicose Veins.

Fluoroscopy-guided foam sclerotherapy for varicose veins in the legs: a retrospective cohort analysis with long-term follow-up

VIEW-VLU observational study of the effect of Varithena on wound healing in the treatment of venous leg ulcers